Literature DB >> 16649237

Catheterization in neonates with pulmonary atresia with intact ventricular septum.

Shakeel A Qureshi1.   

Abstract

Cardiac catheterization is infrequently required in babies with pulmonary atresia with intact ventricular septum. The main indications are to decide on the best form of treatment, the options being determined by the right ventricular as well as infundibular morphology and the presence of right-ventricle dependent coronary circulation. In most cases, an interventional approach is appropriate. This can consist of radiofrequency or laser perforation of the atretic pulmonary valve, combined with balloon dilation. In some patients, additional stenting of the arterial duct may be needed. Copyright 2006 Wiley-Liss., Inc.

Entities:  

Mesh:

Year:  2006        PMID: 16649237     DOI: 10.1002/ccd.20690

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  5 in total

1.  Decreased incidence of right-ventricular outflow tract complications using a retrograde snare technique for radiofrequency pulmonary valve perforation.

Authors:  Luke Lamers; Byron Garn; Eric Ellsworth; Joseph N Graziano
Journal:  Pediatr Cardiol       Date:  2012-03-31       Impact factor: 1.655

Review 2.  The causes of Charcot-Marie-Tooth disease.

Authors:  P Young; U Suter
Journal:  Cell Mol Life Sci       Date:  2003-12       Impact factor: 9.261

Review 3.  [Catheter interventions for congenital heart disease].

Authors:  Thomas Krasemann
Journal:  Herz       Date:  2009-01-08       Impact factor: 1.443

Review 4.  Innovative interventional catheterization techniques for congenital heart disease.

Authors:  Jeffrey D Zampi; Wendy Whiteside
Journal:  Transl Pediatr       Date:  2018-04

5.  Transcatheter Approach for Critical Pulmonary Stenosis or Pulmonary Atresia with Intact Ventricular Septum in Young Infants Using the Simmons Catheter.

Authors:  Jian Wang; Jing Sun; Jian Shen; Jianping Yang; Ling Yang; Pengjun Zhao; Sun Chen
Journal:  J Interv Cardiol       Date:  2020-05-19       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.